Harrow Earns Three ASCRS 2026 Presentations on VEVYE 0.1% and ILEVRO 0.3% Data
Harrow has three scientific abstracts on its ophthalmic treatments VEVYE 0.1% and ILEVRO 0.3% accepted for presentation at the ASCRS 2026 Annual Meeting in Washington, D.C. The research covers real-world treatment patterns in dry eye disease, post-fungal keratoplasty and reduction of visual acuity loss after cataract surgery.
1. Presentation Acceptance
Harrow announced acceptance of three abstracts for presentation at the ASCRS 2026 Annual Meeting, taking place April 10–13 in Washington, D.C. This marks the company’s growing scientific engagement within the ophthalmology community.
2. Abstract Details
Two abstracts focus on VEVYE 0.1% cyclosporine outcomes in dry eye disease and post-fungal keratoplasty, both scheduled April 11 from 8:00–9:30 AM. A third session on April 12 from 8:00–9:30 AM presents a post-hoc analysis of ILEVRO 0.3% nepafenac reducing visual acuity loss after cataract surgery.
3. Clinical and Market Implications
These presentations aim to validate Harrow’s evidence-based therapies, potentially driving physician adoption and supporting market differentiation. The exposure at one of the largest ophthalmic surgeon gatherings could bolster clinical confidence and influence future prescribing trends.